WorldHeart Receives Going Concern Qualification in its 2006 Audit Report

    OAKLAND, Calif., March 30 /CNW/ -- World Heart Corporation (Nasdaq:   WHRT;
TSX: WHT), a developer of mechanical circulatory support systems, in
compliance with Nasdaq Marketplace Rule 4350(b)(1)(B), today announced that
the Company's independent auditors included an explanatory paragraph in the
Company's recently filed Annual Report on Form 10-KSB for the year ended
December 31, 2006, relating to the Company's ability to continue as a going
    WorldHeart ended 2006 with cash and cash equivalents of $12.2 million,
compared with $10.7 million at year-end 2005.  The Company completed a $14.1
million private placement with existing and new investors during the fourth
quarter of 2006.  In conjunction with the financing, the Company restructured
its operations to reduce operating expenses and realigned resources toward
development of the Company's next-generation products.  Management continues
to control spending and manage working capital to preserve cash.
    "WorldHeart will continue to focus its energies on the final development,
evaluation, regulatory approval and commercialization of our next-generation
Levacor Rotary VAD," said Jal S. Jassawalla, President and Chief Executive
Officer of WorldHeart.  "We expect to initiate clinical use of the Levacor(TM)
Rotary VAD in Canada in the near-term and start a U.S. feasibility trial in
the latter half of 2007.  We look forward to continuing to execute on our
business plans, providing important, life-saving products."

    About WorldHeart
    World Heart Corporation is a developer of mechanical circulatory support
systems with leading next-generation technologies, headquartered in Oakland,
California, with additional facilities in Salt Lake City, Utah and in Heesch,
Netherlands.  WorldHeart's registered office is Ottawa, Ontario, Canada.

    Any forward-looking statements in this release are made pursuant to the
safe harbor provisions of the Private Securities Litigation Reform Act of 1995
and include statements relating to the Company's focus on the development of
its next-generation Levacor Rotary VAD and the timing and scope of the
additional clinical trials, and the Company's ability to execute its business
plans, as well as other statements that can be identified by the use of
forward-looking language.  Investors are cautioned that all forward-looking
statements involve risk and uncertainties, including without limitation: risks
in product development and market acceptance of and demand for the Company's
products; need for significant additional financing; progress and timing,
associated with clinical trials, particularly its Levacor Rotary VAD product;
slower Destination Therapy adoption rate for VADs and other risks detailed in
the Company's filings with the United States Securities and Exchange
Commission, including its Annual Report on Form 10-KSB for the year ended
December 31, 2006.

For further information:

For further information: Mr. Richard Juelis, +1-510-563-4713, or Ms.
Peggy  Allman +1-510-563-4721, both of World Heart Corporation Web Site:

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890